Obiltoxaximab

(Anthim®)

Obiltoxaximab

Drug updated on 10/30/2024

Dosage FormInjection (intravenous; 600 mg/6 mL [100 mg/mL])
Drug ClassMonoclonal antibodies against B. anthracis
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in adult and pediatric patients for treatment of inhalational anthrax due to B
  • anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
  • Effectiveness in Animal Models: Obiltoxaximab increased survival rates after anthrax exposure in New Zealand White Rabbits and Cynomolgus Macaques, demonstrating effectiveness in these specific animal models.
  • Lack of Comparative Data: The reviewed studies did not include data comparing the effectiveness of obiltoxaximab with other treatments, so no comparative conclusions can be drawn.
  • Safety in Human Studies: Obiltoxaximab was well-tolerated in healthy human volunteers, with a relatively low incidence of adverse events reported.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Anthim (obiltoxaximab) Prescribing Information.2023Elusys Therapeutics, Inc., Parsippany, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection2017The Annals of pharmacotherapy

Clinical Practice Guidelines